Pujols Mayobanex 4

What Happened
Pujols Mayobanex, Chief Technology Officer of Kyverna Therapeutics (KYTX), received a derivative equity award on February 9, 2026 for 300,000 shares. The reported acquisition price is $0.00 (derivative award/option), resulting in no immediate cash outlay. This was a grant of equity compensation rather than an open-market buy or sell.

Key Details

• Transaction date: 2026-02-09; Form 4 filed: 2026-02-11 (timely filing).
• Transaction type/code: Award/Grant (derivative) — Code A.
• Shares/options granted: 300,000; reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Vesting footnote: 1/4 vests on Feb 9, 2027, then 1/48 of the total shares vests each month thereafter, subject to continuous service.
• No immediate sale or exercise reported in this filing.

Context
This filing documents an equity compensation grant (an option-type award) that aligns the executive's interests with shareholders but is not a market purchase or sale. The award vests over a typical one-year cliff then monthly schedule (four-year total), and there is no indication in this filing of any immediate exercise or cashless transaction.